+743.4%
AXTI vs MRNA
-67.9%
+811.2%
-88.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.1% | +5.4% | -5.3% | -0.1% |
| 7D | +5.1% | -1.1% | +6.2% | +5.1% |
| 30D | -17.5% | +126.1% | -143.6% | -24.3% |
| 3M | -26.7% | +190.0% | -216.7% | -36.7% |
| 6M | +36.8% | +157.2% | -120.5% | +20.6% |
| YTD | +296.1% | +388.2% | -92.1% | +197.3% |
| 1Y | +1,810.6% | +467.0% | +1,343.6% | +1,273.8% |
| 3Y | +2,587.6% | +36.1% | +2,551.5% | +2,366.5% |
| All | +743.4% | -67.9% | +811.2% | +793.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling